Group 1 - Morgan Stanley has raised the target price for MicroPort Scientific Corporation-B (02252) from HKD 30.9 to HKD 42, maintaining an "Overweight" rating and identifying it as a top choice among Chinese medical technology stocks [1] - The company has seen strong global order momentum, with cumulative surgical robot orders exceeding 170 units as of last Wednesday, up from 150 units at the end of August [1] - The installation of the Toumai (four-arm laparoscopic surgical robot) is accelerating globally, with applications in nearly 40 countries and major hospital systems, driving strong adoption [1] Group 2 - Based on approximately 100 cumulative orders for Toumai, the company has increased its installation forecast for this year from 84 units to 105 units, primarily due to growth overseas and the assumption that orders can be converted to sales within less than a quarter [1] - The higher installation base and improved product mix are expected to lead to a gross margin improvement of 1 to 1.5 percentage points [1]

Group 1 - Morgan Stanley believes that Luoyang Molybdenum (603993)(03993) will see an absolute increase in stock price within the next 30 days, estimating a probability of about 70% to 80% for this scenario, maintaining an "Overweight" rating and a target price of HKD 11.7, based on discounted cash flow valuation [1] - The Democratic Republic of Congo has announced an extension of the cobalt export ban until October 15, followed by the implementation of export quotas, with quotas for 2026 to 2027 set at 40% of normal production [1] - Assuming Luoyang Molybdenum can obtain a quota ratio similar to the national level, its potential sales volume could reach approximately 8,600 tons in Q4 2025 and 43,600 tons in 2026 to 2027, with significant impacts expected on cobalt supply due to the DRC accounting for 70% of global supply [1]

Core Viewpoint - 招银国际 expresses confidence in the global development of 科伦博泰生物-B (06990) SKB264, raising the target price from HKD 299.93 to HKD 498.55, maintaining a "Buy" rating based on discounted cash flow valuation [1] Financial Performance - In the first half of the year, the company reported revenue of RMB 950 million, with product sales amounting to RMB 310 million, of which SKB264 contributed RMB 302 million, representing 34% of the annual forecast [1] - The company recorded cooperation and R&D service income of RMB 641 million, which includes an upfront payment for the licensing of SKB378 (TSLP) to WindwardBio and milestone payments from Merck [1] Product Development - SKB264 has been approved for the treatment of late-line triple-negative breast cancer (TNBC) and EGFR mutation non-small cell lung cancer (NSCLC), currently in the early stages of accelerated growth [1] - The management maintains a sales target for SKB264 of RMB 800 million to RMB 1 billion for the full year, with expectations that the two approved indications will be included in the national medical insurance catalog starting early next year [1] Financial Position - The total value of cash and financial assets is RMB 4.46 billion, providing sufficient funds for commercialization and R&D development [1]